Genetic mutations could be therapeutic target in lung cancer
Researchers have uncovered the genetic basis of multiple primary lung cancers, shedding light on potential therapeutic targets for treatment.
A team of researchers, led by Professor Motoshi Suzuki from the Department of Molecular Oncology, Fujita Health University, Japan, along with graduate student Dat Quoc Tran from the university, distinguished inherited germline variants from tumour-acquired mutations.
The scientists employed genomic sequencing techniques to investigate lung cancer tumours, analysing 26 LUAD tumours from 11 patients with multiple lung cancers using targeted next-generation sequencing covering 143 cancer-related genes.
The results revealed that nine of 11 patients had true multiple primary lung cancers, while one had intrapulmonary metastasis and one exhibited features of both conditions, underscoring the value of combining genomic profiling with conventional pathology for accurate diagnosis.
The researchers also identified two previously unreported truncating germline variants in BRCA2. One was detected across three independent tumours in a single patient, while the second was found in an unrelated patient who lacked the common driver mutations typically associated with LUAD.
These findings suggest that inherited BRCA2 alterations may contribute to susceptibility to multiple primary lung cancers.
“Although germline pathogenic variants (GPVs) have transformed the understanding and management of some cancers, their role in lung adenocarcinoma (LUAD) has remained largely unexplored,” Suzuki said.
“We identified BRCA2 likely GPVs in patients with multiple primary LUAD. Thus, PARP inhibitors and other molecularly targeted approaches directed at BRCA2-related DNA repair deficiencies may eventually become viable treatment options for patients with these specific genetic backgrounds.”
